| Burkhardt, Jan-Karl |
| Active, not recruiting | N/A | 246 | US | Treatment of Intracranial Aneurysms | Medtronic Neurovascular Clinical Affairs | Intracranial Aneurysm | 03/26 | 04/28 | | |
| Recruiting | N/A | 1000 | US | MicroVention Mechanical Thrombectomy Devices as first-line treatment | Microvention-Terumo, Inc. | Acute Ischemic Stroke, Vessel Occlusion, Stroke, Ischemic | 12/25 | 12/25 | | |
WEB PAS, NCT04839705: Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device |
|
|
| Recruiting | N/A | 180 | US | WEB | Microvention-Terumo, Inc. | Wide Neck Bifurcation Intracranial Aneurysms | 12/25 | 12/29 | | |
| Recruiting | N/A | 150 | US | Citadel Embolization Device | Stryker Neurovascular | Unruptured Wide-neck Aneurysms | 06/26 | 06/26 | | |
NCT05409989: MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study |
|
|
| Recruiting | N/A | 154 | US | FRED™ X™, Flow Re-Direction Endoluminal Device X | Microvention-Terumo, Inc. | Intracranial Aneurysm | 09/29 | 11/29 | | |
| Gill, Saar |
ALLOHA, NCT05473910: A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation |
|
|
| Recruiting | 1 | 63 | US | SOC + TSC-100, SOC + TSC-101, Control | TScan Therapeutics, Inc. | AML, Myelodysplastic Syndromes, ALL, Adult | 12/25 | 06/26 | | |
| Not yet recruiting | 1 | 12 | NA | CART123 Cells, Ruxolitinib 10 MG Oral Tablet, Ruxolitinib 5 MG | University of Pennsylvania, Novartis | Relapsed AML, Refractory AML | 03/45 | 03/45 | | |
| Bajaj, Archna |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
| Recruiting | 3 | 1328 | Europe, Canada, US, RoW | Plozasiran Injection, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Hypertriglyceridemia | 07/26 | 10/26 | | |
| Recruiting | 3 | 300 | Europe, Canada, US, RoW | Plozasiran Injection, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Severe Hypertriglyceridemia | 07/26 | 10/26 | | |
| Recruiting | 2 | 30 | US | obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks, Repatha | NewAmsterdam Pharma | Dyslipidemias | 10/25 | 12/25 | | |
NCT05646381: A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis |
|
|
| Recruiting | 2 | 502 | Europe, Canada, US, RoW | Pelacarsen (TQJ230) 80mg, TQJ230, Matching placebo, Placebo | Novartis Pharmaceuticals | Aortic Stenosis | 01/29 | 01/29 | | |
NCT05972278: Investigating the Effect of Obicetrapib on Lipoprotein Metabolism |
|
|
| Active, not recruiting | 1 | 22 | US | Obicetrapib, tablets | NewAmsterdam Pharma, University of Pennsylvania | Lipid Metabolism | 09/24 | 10/24 | | |
| Morgan, Jennifer |
| Active, not recruiting | N/A | 60 | US | Axonics System | Axonics, Inc. | Overactive Bladder Syndrome, Urinary Urge Incontinence, Sacral Neuromodulation | 10/23 | 12/24 | | |
NCT06186765: F15 Recharge Free Axonics SNM System Clinical Study |
|
|
| Recruiting | N/A | 130 | Europe, US | Axonics SNM System (Model 4101) | Axonics, Inc. | Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI) | 03/25 | 06/26 | | |
